Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

NCT07014254 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
Adenocarcinoma of the Stomach
Colorectal Cancer Metastatic
Neuroendocrine Tumor (NET)

Interventions

DRUG: 177Lu-CTR-FAPI nuclide-targeted therapy

Sponsor

Xijing Hospital